CIK 0001808865
ITOS iTeos Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Aug 29, 2025.
iTeos Therapeutics, Inc. (ITOS) has 21 SEC Form 4 filings on file from 12 insiders, the latest filed on Aug 29, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
8 open-market trades have been scored at ITOS. The newest: Michel Detheux (Chief Executive Officer) sold $1.0M of stock on Jun 9, 2025, filed Jun 11, 2025, scored 43 (moderate), under a 10b5-1 plan. The largest of the 8 shown: EcoR1 Capital, LLC (10% owner) bought $39M on May 14, 2025, scored 42 (moderate). 2 insiders sold within 14 days of each other around Jun 9, 2025.
8 Form 144 notices of planned sales are on file, the latest filed Jun 10, 2025.
Last 90 days
Signals
Open-market buys and sells at iTeos Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Michel Detheux Chief Executive Officer sell | $1.0M 104,565 shares | -72% | - | |
| 43Moderate | Michel Detheux Chief Executive Officer sell | $1.6M 156,847 shares | -109% | - | |
| 33Weak | David Hallal director sell | $1.2M 114,682 shares | -300% | - | |
| 42Moderate | EcoR1 Capital, LLC owner buy | $39M 4,958,978 shares | +87% | - | |
| 53Moderate | MPM BioVentures 2014, L.P. other sell | $5.1M 630,191 shares | -23% | - | |
| 53Moderate | Ansbert Gadicke other sell | $8.3M 1,031,931 shares | -23% | - | |
| 53Moderate | Mpm Bioventures 2018, L.p. other sell | $5.1M 630,191 shares | -23% | - | |
| 31Weak | Matthew Gall Chief Financial Officer buy | $39k 5,000 shares | +8% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 10, 2025 | Detheux Michel Officer | 52,283 0.14% of outstanding | $524k | Jun 10, 2025 | $2.1M |
| Jun 9, 2025 | Detheux Michel Officer | 52,282 0.14% of outstanding | $532k | Jun 9, 2025 | $1.6M |
| Jun 6, 2025 | Detheux Michel Officer | 52,282 0.14% of outstanding | $533k | Jun 6, 2025 | $1.1M |
| Jun 6, 2025 | DAVID L HALLAL Director | 38,228 0.10% of outstanding | $391k | Jun 6, 2025 | $773k |
| Jun 5, 2025 | Detheux Michel Officer | 52,282 0.14% of outstanding | $534k | Jun 5, 2025 | $528k |
| Jun 5, 2025 | DAVID L HALLAL Director | 38,227 0.10% of outstanding | $388k | Jun 5, 2025 | $385k |
| Jun 4, 2025 | Detheux Michel Officer, President and CEO | 52,283 0.14% of outstanding | $526k | Jun 4, 2025 | none |
| Jun 4, 2025 | DAVID L HALLAL Director | 38,227 0.10% of outstanding | $385k | Jun 4, 2025 | none |
Transactions
The newest 50 of 90 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 29, 2025 | David Feltquate Chief Medical Officer | UTender of shares Common Stock | -47,000 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Gall Chief Financial Officer | UTender of shares Common Stock | -89,429 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Call Chief Operating Officer | UTender of shares Common Stock | -161,898 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | David K Lee director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,141 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | David Hallal director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,140 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | UTender of shares Common Stock | -153,903 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Ann D Rhoads director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,178 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Yvonne McGrath Chief Scientific Officer | UTender of shares Common Stock | -46,300 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Call Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,063 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | David Hallal director | DDisposition to issuer Stock Option (Right to Buy)derivative | -146,160 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Gall Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,063 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | UTender of shares Common Stockindirect: By MG3A | -94,027 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | David K Lee director | DDisposition to issuer Stock Option (Right to Buy)derivative | -23,625 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Yvonne McGrath Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -91,000 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Gall Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -135,937 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,185 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Call Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -135,937 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Yvonne McGrath Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -69,069 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -444,815 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Call Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -41,694 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Gall Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,388 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Yvonne McGrath Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,054 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Call Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -66,170 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -94,336 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Gall Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,123 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Gall Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -252,135 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Call Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,074 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,128 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,544 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Matthew Call Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -146,835 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By MG3A | -185,000 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | Michel Detheux Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By MG3A | -52,700 | - | - | 0 | Aug 29, 2025 |
| Jun 9, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 11, 2025 |
| Jun 9, 2025 | Michel Detheux Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.03 | $84k | 135,903 | Jun 11, 2025 |
| Jun 9, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,882 | $4.30 | $189k | 43,882 | Jun 11, 2025 |
| Jun 9, 2025 | Michel Detheux Chief Executive Officer | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,882 | $10.03 | $440k | 0 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.02 | $84k | 135,903 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,883 | $4.30 | $189k | 43,883 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,883 | $10.02 | $440k | 0 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Common Stock10b5-1 | +18,000 | $4.30 | $77k | 153,903 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Common Stockindirect: By MG3A10b5-1 | +94,027 | $4.30 | $404k | 94,027 | Jun 11, 2025 |
| Jun 9, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 26,400 | Jun 11, 2025 |
| Jun 9, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,882 | $0.00 | $0 | 137,913 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 18,000 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,883 | $0.00 | $0 | 94,030 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,000 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Jun 10, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -94,027 | $0.00 | $0 | 3 | Jun 11, 2025 |
| Jun 4, 2025 | David Hallal director | MOption exercise Common Stock10b5-1 | +38,227 | $4.30 | $164k | 38,227 | Jun 6, 2025 |
| Jun 4, 2025 | Michel Detheux Chief Executive Officer | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 6, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Matthew CallChief Operating Officer
- Michel DetheuxChief Executive Officer
- EcoR1 Capital, LLCowner, director
- David FeltquateChief Medical Officer
- Ansbert Gadickeowner, other
- Matthew GallChief Financial Officer
- David Hallalceo, officer, director
- David K Leedirector
- Mpm Bioventures 2018, L.p.owner, other
- MPM BioVentures 2014, L.P.owner, other
- Yvonne McGrathChief Scientific Officer
- Ann D Rhoadsdirector
Questions about ITOS
Answered from the filings on this page, as of the latest one.
Are insiders buying ITOS?
No. In the last 90 days no insider at iTeos Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ITOS on the open market?
Michel Detheux (Chief Executive Officer) sold $1.0M of ITOS on Jun 9, 2025 and filed the Form 4 on Jun 11, 2025. InsiderTell scored 43 (moderate), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at iTeos Therapeutics, Inc.?
12 people have filed a Form 4 at iTeos Therapeutics, Inc., among them Matthew Call (Chief Operating Officer), Michel Detheux (Chief Executive Officer), EcoR1 Capital, LLC (10% owner and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.